Procter And Gamble
As of the edition of 20 October 2026, Procter And Gamble runs 16 drugs, 11 of them marketed; it is on route A at 3 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 11 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 16 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Estradiol | Ends 2032 (patent) | 6 |
| Chlorhexidine | none listed | 0 |
| Mesalamine | Ends 2027 (patent) | 12 |
| Risedronic acid | none listed | 2 |
| Tetracycline | none listed | 0 |
| Nystatin | none listed | 0 |
| Nitrofurantoin | none listed | 0 |
| Dantrolene | none listed | 2 |
| Etidronic acid | none listed | 0 |
| Pyrithione | none listed | 0 |
| Saralasin | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 3 targets, route B at 1 target.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Procter And Gamble needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mouth and teeth: 6 trials led
- Immune system: 4 trials led
- Infections: 3 trials led